IDEAYA Biosciences, Inc. $IDYA Position Decreased by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 61.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 174,265 shares of the company’s stock after selling 272,155 shares during the period. JPMorgan Chase & Co. owned about 0.20% of IDEAYA Biosciences worth $4,742,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd bought a new stake in IDEAYA Biosciences during the third quarter worth approximately $38,000. Abich Financial Wealth Management LLC bought a new position in shares of IDEAYA Biosciences in the third quarter valued at $58,000. Daiwa Securities Group Inc. lifted its position in shares of IDEAYA Biosciences by 16.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock valued at $66,000 after acquiring an additional 436 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of IDEAYA Biosciences by 16.1% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,881 shares of the company’s stock valued at $106,000 after acquiring an additional 537 shares during the last quarter. Finally, Osaic Holdings Inc. boosted its stake in shares of IDEAYA Biosciences by 59.1% during the 2nd quarter. Osaic Holdings Inc. now owns 7,443 shares of the company’s stock worth $148,000 after acquiring an additional 2,764 shares in the last quarter. 98.29% of the stock is owned by institutional investors and hedge funds.

IDEAYA Biosciences Stock Up 0.8%

Shares of NASDAQ:IDYA opened at $32.74 on Friday. The company’s fifty day moving average is $32.73 and its two-hundred day moving average is $32.18. The company has a market cap of $2.87 billion, a P/E ratio of -24.99 and a beta of 0.02. IDEAYA Biosciences, Inc. has a 12-month low of $13.45 and a 12-month high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, February 17th. The company reported ($0.94) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.09. The business had revenue of $21.75 million during the quarter, compared to analyst estimates of $5.95 million. The business’s quarterly revenue was up 55.7% on a year-over-year basis. During the same period last year, the business earned ($1.49) EPS. Equities research analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

Analysts Set New Price Targets

IDYA has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a research report on Wednesday, February 18th. Guggenheim reiterated a “buy” rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a research report on Wednesday, February 18th. Citigroup lifted their price target on IDEAYA Biosciences from $64.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Truist Financial boosted their price objective on IDEAYA Biosciences from $59.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Finally, UBS Group assumed coverage on shares of IDEAYA Biosciences in a research note on Wednesday, January 7th. They set a “buy” rating and a $50.00 price objective for the company. Fifteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $48.69.

Insider Buying and Selling

In other IDEAYA Biosciences news, Director Jeffrey Stein acquired 50,000 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was purchased at an average cost of $32.96 per share, for a total transaction of $1,648,000.00. Following the transaction, the director owned 54,281 shares of the company’s stock, valued at $1,789,101.76. The trade was a 1,167.95% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.50% of the company’s stock.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.